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Abstract
MicroRNAs miR-122, miR-34a, miR-16 and miR-21 are commonly deregulated in liver fibrosis and hepatocellular carcinoma.
This study examined whether circulating levels of these miRNAs correlate with hepatic histological disease severity in
patients with chronic hepatitis C infection (CHC) or non-alcoholic fatty-liver disease (NAFLD) and can potentially serve as
circulating markers for disease stage assessment. We first used an in vitro model of hepatitis C virus (HCV) infection to
measure the extracellular levels of these four miRNAs. Whereas miR-21 extracellular levels were unchanged, extracellular
levels of miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection,
independently of viral replication and production. Similarly, in CHC patients, serum levels of miR-122, miR-34a and miR-16
were significantly higher than in control individuals, while miR-21 levels were unchanged. There was no correlation between
the serum levels of any of these microRNAs and HCV viral loads. In contrast, miR-122 and miR-34a levels positively correlated
with disease severity. Identical results were obtained in an independent cohort of CHC patients. We extended the study to
patients with NAFLD. As observed in CHC patients, serum levels of miR-122, miR-34a and miR-16 were significantly higher in
NAFLD patients than in controls, while miR-21 levels were unchanged. Again, miR-122 and miR-34a levels positively
correlated with disease severity from simple steatosis to steatohepatitis. In both CHC and NAFLD patient groups, serum
levels of miR-122 and miR-34a correlated with liver enzymes levels, fibrosis stage and inflammation activity. miR-122 levels
also correlated with serum lipids in NAFLD patients. Conclusion: Serum levels of miR-34a and miR-122 may represent novel,
noninvasive biomarkers of diagnosis and histological disease severity in patients with CHC or NAFLD.
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Introduction
Liver biopsy is often recommended in patients with unexplained
elevated serum aminotransferases in order to determine the cause,
to stage hepatic fibrosis and to grade hepatic inflammation. Non-
invasive methods that can evaluate disease severity and the
likelihood of disease progression in persons with elevated liver
enzymes need to be developed. MicroRNAs are small non-coding
RNAs that control translation and transcription of many genes.
They are receiving growing attention because of numerous reports
on their dysregulation in human diseases and their potential as
diagnostic and therapeutic targets. Because of their stability and
presence in almost all body fluids, miRNAs constitute a novel class
of non-invasive biomarkers. Numerous studies have shown that
aberrant miRNA expression is associated with the development and
progression of various types of human cancer and therefore studies
on circulating miRNA profiles largely focused on cancer [1–3].
This study examined whether serum levels of selected miRNAs,
thought to be deregulated in liver disease, can serve as non-
invasive biomarkers of diagnosis and histological severity in
patients with chronic hepatitis C (CHC) or non-alcoholic fatty
liver disease (NAFLD). The highly abundant liver-specific miR-
122, is of particular interest. miR-122 is known to regulate
metabolic pathways in the liver, including cholesterol biosynthesis
[4–7]. miR-122 also positively regulates hepatitis C virus (HCV)
replication and viral production [8–10]. Reduced expression of
miR-122 has been observed in hepatocellular carcinoma (HCC),
often in advanced tumors of poor prognosis [11–13] although an
upregulation of miR-122 was also reported in HCV-derived HCC
[11,14]. miRNAs encoded by the miR-15/16 cluster act as tumor
suppressors and are down-regulated in several human cancers
[15]. In contrast, miR-21 was identified to be consistently
upregulated in many cancers [16] including HCC [17]. Upregula-
tion of miR-21 was also found in highly fibrotic HCV-infected
human livers [18]. miR-34a, a central mediator of p53 function
[19], has recently emerged as another miRNA modulated in liver
disease. Interestingly, while most studies report a downregulation
of miR-34a in human cancers [19], miR-34a was found increased
in HCC [17] as well as in a mouse model of steatohepatitis [20].
We selected these four miRNAs (miR-122, miR-16, miR-21 and
miR-34a) for the present study aimed at investigating their levels in
serum of patients with CHC and NAFLD with a wide spectrum of
histological disease severity. In addition to this analysis on human
sera, we used an in vitro model of HCV infection to measure
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23937extracellular levels of these same miRNAs in supernatant of HCV-
infected cells.
Materials and Methods
Ethics Statement
The study protocol conforms fully to the ethical guidelines of the
1975 Declaration of Helsinki and was approved by the
Institutional Review Board of the Fred Hutchinson Cancer
Research Center. We used only fully de-identified samples that
were transferred from formal sample repositories at the University
of Michigan and the Veterans Affairs Puget Sound Health Care
System. Written, informed consent was obtained from every
human subject when the samples were originally collected for the
repositories under the terms of study protocols approved by the
Institutional Review Boards at these respective institutions.
In vitro HCV infection and HCV RNA quantitation
HCV viral stocks were generated following transfection of in vitro
transcripts of the HCVJ6/JFH genotype 2a strain (kindly provided
by Dr. Charles Rice) using DMRIE-C (Invitrogen). Huh7.5 cells
were infected with HCVcc, at a dose of 5.6610
3 TCID50/ml as
described [21] and cultured for 15 days, corresponding to 4
passages. Cells and supernatants were collected at five, ten and
fifteen days post-infection, 48 hrs after the cells were split and
seeded at a density of 2610
5 cells/cm
2. The confluence of the cells
at the time of collection was 70-80%. Intracellular and
extracellular RNA was extracted using the miRNeasy extraction
kit (QIAGEN). Samples were submitted to DNAse digestion,
reverse-transcription using random hexamers, and real-time PCR
using the following HCV primer sequences: 5-CGGGAGAGC-
CATAGTGGTCTGCG-3 and 5-CTCGCAAGCACCCTAT-
CAGGCAGTA-3. To determine HCV copy numbers, standard
curves were prepared by serial dilution of a plasmid bearing the
amplified HCV sequence.
Patient Groups (Table S1)
The Control group was composed of 19 healthy individuals
without any evidence of liver disease. The Chronic Hepatitis C
(CHC) group was composed of a first set of 18 patients recruited at
the University of Michigan and of an independent set of 35
patients recruited as part of an ongoing observational study of
chronic liver disease at Veterans Affairs Puget Sound Health Care
System. HCV infection was defined by presence of HCV RNA in
serum. The Non-Alcoholic Fatty Liver Disease (NAFLD) group
was composed of 34 patients also enrolled at Veterans Affairs
Puget Sound Health Care System. NAFLD was defined by the
presence of hepatic steatosis in at least 5% of hepatocytes, in the
absence of HCV RNA and hepatitis B virus surface antigen, self-
reported alcohol consumption in the preceding six months, or
histological features suggestive of primary biliary cirrhosis,
autoimmune hepatitis, or iron overload.
For hepatic histology assessment, formalin-fixed liver tissue was
stained with hematoxylin and eosin, Masson’s trichrome and special
stains for iron and copper and reviewed independently by a liver
pathologist, who was blinded to this study. For CHC patients, the
BattsandLudwigscoringsystem[22] wasusedtoscorefibrosis(0–4)
and inflammation (0–4). For NAFLD patients, steatosis, ballooning
Figure 1. Differential expression of miRNAs in supernatant of HCV-infected cells. (A) Detection of intracellular and extracellular HCV RNA.
(B) miR-122, miR-34a, miR-16 and miR-21 levels in uninfected and HCV-infected Huh7.5 cells at 5, 10 and 15 days post-infection. Cycle threshold (CT)
values were converted to an absolute value based on the standard curve. The expression levels are presented as the mean 6 standard error of the
mean (SEM) (copy number/ml of supernatant or copy number/mg of total RNA) of three independent experiments.
doi:10.1371/journal.pone.0023937.g001
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the currently accepted scoring system [23]. In this scoring system,
the scores for steatosis grade (0–3), lobular inflammation (0–3), and
ballooning (0–2) can be summed to yield a NAFLD Activity Score
(NAS) with scores $5 being considered diagnostic for histological
steatohepatitis while scores of 1–4 are diagnostic of simple steatosis.
miRNA quantitation
Total RNAwith preserved miRNAs was extractedfrom 100 mlo f
serum by miRNeasy extraction kit and using a plasma/QIAzol ratio
of 1:10. Synthetic spiked-in C. elegans miR-238 was added to the
serum and cell supernatant samples prior to RNA extraction as
internal control and RNU44 was quantified in the cellular RNA
samples. Expression of mature miRNAs was detected using the
Taqman miRNA qRT-PCR Assay (Applied Biosystems, Carlsbad,
CA). Reverse transcription and PCR reactions were run in triplicate
intheAppliedBiosystems7900 System.To determinemiRNAcopy
numbers, standard curves were prepared by serial dilution of
synthetic miRNA (Integrated DNA Technologies, Coralville, IA).
Statistical Analysis
Statistical significance of differences between groups was
analyzed by Wilcoxon rank sum test using TIBCO Spotfire S+
(TIBCO Spotfire, Somerville, MA). Correlation analysis was
performed using two-tailed Pearson correlation test. Receiver
operating characteristic (ROC) analysis was undertaken using R
software version 2.9.2.
Results
Increased levels of miR-122, miR-34a and miR-16 in the
supernatant of HCV-infected cells
Intracellular and extracellular levels of miR-122, miR-34a,
miR-16 and miR-21 were measured in Huh7.5 cells infected with
a genotype 2a chimeric HCV, after confirming the absence of
confounding miRNAs in the bovine serum used to culture the
cells. Copy numbers of the targeted miRNAs and of the HCV
RNA were calculated at five, ten and fifteen days post-infection in
three independent experiments. HCV RNA reached the highest
levels at 10 days post-infection in both the intracellular and
extracellular compartments (4.9610
10 copies/mg and 0.96
10
10 copies/ml, respectively) (Figure 1A). Among the four
miRNAs analyzed, miR-122 was the most abundant in both the
intracellular and extracellular compartments (3.7610
9 copies/mg
of total RNA and 4.4610
6 copies/ml of supernatant, respectively)
and miR-34a the least abundant with 1.8610
6 intracellular
copies/mg of total RNA and undetectable extracellular levels
(Figure 1B). miR-16 and miR-21 abundances were largely similar
with 1.6610
9 intracellular copies/mg of total RNA for both
miRNAs, 7.6610
5 copies/ml for extracellular miR-16 and
9610
5 copies/ml of supernatant for extracellular miR-21 (Figure
1B). Intracellular levels of miR-122, miR-16 and miR-21
remained constant during the infection while intracellular miR-
34a levels increased by 2.3-fold at 5 days post-infection and by 3.2-
fold at 10 and 15 days post-infection (Figure 1B). At 10 days post-
infection, corresponding to the highest levels of HCV RNA,
extracellular levels of miR-122 and miR-16 increased by 3.3-fold
and 2.1-fold, respectively, while miR-21 remained unchanged.
miR-34a levels were undetectable in supernatant of uninfected
Huh7.5 cells as well as in cells infected with HCV for 5 days, but
increased to detectable levels at 10 days post-infection. At 15 days
post-infection, corresponding to a decline in HCV RNA levels,
extracellular miR-122, miR-34a and miR-16 levels further
increased by 6.9-, 6.2- and 2.9-fold, respectively and a 6-fold
accumulation of miR-21 was observed (Figure 1B).
Increased serum levels of miR-122, miR-34a and miR-16
in chronic hepatitis C patients
We then investigated whether these miRNAs are detected and
modulated in serum from patients with chronic hepatitis C (CHC).
In healthy control sera, levels of miR-16 (3.1610
6 copies/ml) were
higher than levels of miR-21 (1.6610
6 copies/ml) and miR-122
(2.8610
5 copies/ml), and miR-34a was undetectable, the detec-
tion limit of the assay being approximately 0.3610
4 copies/ml.
Serum levels of miR-122 and miR-16 were significantly higher in a
first set of patients with CHC (n=18) compared to healthy
Figure 2. Up-regulation of serum miR-122, miR-34a and miR-16 in chronic hepatitis C patients. Serum levels of miR-122, miR-34a, miR-16
and miR-21 in (A) a first set of 18 CHC patients and (B) an independent set of 35 CHC patients. CT values were converted to an absolute value based
on the standard curves. Serum miRNA expression levels are expressed in copy number/ml. In the box-plot displays, the bold line indicates the median
per group, the box represents 50% of the values and horizontal lines show minimum and maximum values of the calculated non-outlier values. For
miR-34a, the dashed lines represent the levels corresponding to CT values between 35 and 37 (1.2610
4 – 0.3610
4copies/ml).
doi:10.1371/journal.pone.0023937.g002
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respectively) and miR-34a levels increased from undetectable
levels to a median level of 4.4610
4 copies/ml (Figure 2A). miR-21
levels were not significantly different between controls and CHC
patients (Figure 2A). There was no correlation between the
abundance of any of these four miRNAs and the HCV viral load
measured in these patients (R from -0.08 to 0.08). We validated
these results in an independent group of 35 CHC patients enrolled
at a different site. Confirming the results obtained in the first set of
patients, miR-122 levels were higher by 7.9-fold in CHC patients
compared to controls (p,0.0001), miR-16 levels were higher by
6.3-fold (p,0.0001), miR-34a was undetectable in control sera but
detected at a median of 2.1610
4 copies/ml in the CHC group,
and miR-21 levels were unchanged (Figure 2B). Finally, there was
no correlation between the serum abundance of any of these four
miRNAs and the HCV viral load (R from -0.003 to 0.24).
Based on histology grading, we separated the CHC patients into
patients with early stage fibrosis (F0-F1) and patients with
advanced fibrosis (F3-F4). miR-122 and miR-16 serum levels
were already strongly increased in the CHC-early group
compared to controls (6.4-fold and p,0.0001 for both miRNAs)
and miR-34a levels were detectable in all patients with early
disease, with a median of 1.8610
4 copies/ml (Figure 3A). Serum
levels of miR-122 and miR-34a further increased in the CHC-
advanced group compared to the CHC-early group (2.2-fold
(p=0.009) and 2.6-fold (p=0.002), respectively) (Figure 3A). The
Figure 3. Serum levels of miR-122, miR-34a, miR-16 and miR-21 and histological liver disease severity in CHC patients. CHC group
was subdivided into (A) CHC-early (F0-F1) and CHC-advanced groups (F3-F4) and (B) further subdivided according to individual fibrosis stage.
doi:10.1371/journal.pone.0023937.g003
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while the increase of miR-34a was continuous between F0–F3
(Figure 3B). In contrast to miR-122 and miR-34a, miR-16 serum
levels remained unchanged in the CHC-advanced group com-
pared to the CHC-early group (Figure 3A). There was no
significant difference in miR-21 levels between the CHC-early and
CHC–advanced groups although a slight increase was observed in
patients with F4 stage disease (Figure 3A,B).
Increased serum levels of miR-122, miR-34a and miR-16
in patients with NAFLD.
To determine whether serum levels of miR-122, miR-34a, miR-
16 and miR-21 change in patients with other chronic liver
diseases, we measured these four miRNAs in sera collected from
34 patients diagnosed with NAFLD. miR-122 levels were
increased by 7.2-fold in NAFLD patients compared to healthy
controls (p,0.0001), miR-16 levels were increased by 5.5-fold
(p,0.0001), miR-34a increased from undetectable levels to a
median of 2.2610
4 copies/ml and miR-21 was unchanged
(Figure 4A). We divided the NAFLD patients into two groups
based on the NAFLD activity score (NAS): patients with simple
steatosis (NAFLD-SS) defined by NAS scores 1–4 and patients
with non-alcoholic steatohepatitis (NASH) defined by NAS scores
5–7. Serum levels of miR-122 and miR-16 were higher in
NAFLD-SS compared to the controls (5.7-fold (p,0.0001) and
5.3-fold (p,0.0001), respectively) and miR-34a were detectable in
all patients with simple steatosis with a median of 1.2610
4 copies/
ml. miR-21 levels were unchanged. miR-122 and miR-34a levels
further increased in the NASH group compared to the NAFLD-
SS group (2.0-fold (p=0.05) and 2.8-fold (p=0.009), respectively)
(Figure 4B). For both miRNAs, the increase occurred mostly
between NAS scores 3-4 and NAS score 5 (Figure 4C). miR-16
and miR-21 levels were similar in both groups (Figure 4B).
miR-122 and miR-34a correlation with clinical parameters
and performance in disease stage assessment
Because both miR-122 and miR-34a levels correlate with disease
severity, we investigated the relationship of their serum levels with
Figure 4. Serum levels of miR-122, miR-34a, miR-16 and miR-21 in NAFLD patients. (A) Expression of miR-122, miR-34a, miR-16 and miR-21
in serum from healthy controls and NAFLD patients. (B) NAFLD patients were divided into two groups based on the NAFLD activity score (NAS):
NAFLD-simple steatosis (NAFLD-SS) with NAS#4 and non-alcoholic steatohepatitis (NASH) with NAS $5. (C) NAFLD-SS and NASH groups were further
subdivided based on individual NAS scores.
doi:10.1371/journal.pone.0023937.g004
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NAFLD patients (Table 1). In both patient groups, a strong positive
correlation with alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) was observed for miR-122. High positive
correlations were also observed for miR-122 and miR-34a with
fibrosis stage and inflammation activity. In CHC patients, a positive
correlation was also observed for miR-122 and miR-34a with blood
glucose levels and insulin resistance. In NAFLD patients, a positive
correlation was also observed between miR-122 and total
cholesterol level and low-density lipoprotein (LDL).
In a pilot analysis, we evaluated whether circulating miR-122,
miR-34a and miR-16 can be used to assess the disease stage in
CHC and NAFLD patients. We first performed ROC curve
analyses for miR-16 and miR-122 comparing healthy controls and
early disease (CHC F0-F1 and NAFLD NAS 1-4) (Figure 5A,B).
Because miR-34a was under the limit of detection in controls, such
analysis could not be performed for miR-34a. The area under the
receiver-operator characteristic curve (AUC) values for miR-122
and miR-16 in the comparison between CHC-early and control
groups were 0.90 and 0.92 respectively (Figure 5A). Both miRNAs
performed better than ALT (AUC=0.85). A similar result was
obtained comparing healthy controls and NAFLD-SS with AUC
values of 0.93 for miR-122, 0.96 for miR-16 and 0.91 for ALT
(Figure 5B). When comparing CHC-early and CHC-advanced
patients, miR-34a performed better than miR-122 (AUC=0.84 vs
AUC=0.75) (Figure 5C). Again a similar result was obtained
when comparing NAFLD-SS and NASH (AUC values of 0.75 and
0.70) (Figure 5D).
Discussion
MicroRNA changes in the liver have been reported in disease
processes such as hepatocarcinogenesis and liver fibrosis. There is
however only limited information about their detection in blood
and their correlation with histological disease severity in patients
with chronic liver diseases. We first measured intracellular and
extracellular levels of miR-122, miR-34a, miR-16 and miR-21 in
HCV-infected Huh7.5 cells. miR-122 intracellular levels were not
affected by HCV replication, in agreement with previous reports
[8]. In contrast, miR-122 strongly accumulated in the extracellular
compartment of HCV-infected cells, independently of the levels of
HCV replication and production. These results suggest that there
is no correlation between intracellular and extracellular levels of
miR-122. Similar results were observed for miR-16 although to a
lesser extent. In contrast, miR-34a was increased in both the
intracellular and extracellular compartments upon HCV infection
and miR-21 was only slightly changed. miRNAs are associated
with cell-derived vesicles or exosomes [2] but also with protein
complexes [24]. miR-122 and miR-16 in particular have been
reported associated with argonaute2 complexes and independent
of vesicles in plasma [24]. Future experiments should investigate
the mechanisms leading to the release of these microRNAs from
hepatocytic cells.
In CHC patients and in patients with NAFLD, plasma levels of
miR-122 were elevated compared to healthy controls. In CHC
patients, miR-122 levels correlated with fibrosis stage and
inflammation activity but didn’t correlate with HCV viral load.
An absence of correlation between intrahepatic miR-122 and
HCV RNA levels was also observed in human liver biopsies
[25,26]. In NAFLD patients, miR-122 levels also correlated with
fibrosis stage and inflammation activity. An inverse correlation
between intrahepatic miR-122 and fibrosis [18,26] and reduced
intrahepatic levels of miR-122 in NASH were reported [27].
Altogether, these results are consistent with a lack of correlation
between miR-122 regulation in liver tissue and in serum as
observed in the HCV-infected Huh7.5 cells. Circulating miR-122
levels have been reported to be elevated in patients with chronic
hepatitis B viral infection [28,29] and to correlate with liver
histologic stage, inflammation grades and ALT activity [28].
Serum miR-122 levels were also higher in patients with chronic
hepatitis B infection than in patients with hepatocellular
carcinoma [29]. We are reporting here similar results for miR-
122 in patients with chronic hepatitis C or with NAFLD,
suggesting that the increase in circulating levels of miR-122 is
common to chronic liver disease of all etiologies. Our study is also
in agreement with a recent study reporting an increase in serum
miR-122 levels in patients with chronic hepatitis C virus
Table 1. Correlation between miRNAs and specific clinical parameters.
CHC NAFLD
miR-122 mir-34a miR-122 mir-34a
ALT (IU/L) 59 (26–394)* 0.92 0.86 76 (14–183)* 0.75 0.45
AST (IU/L) 47 (23–336)* 0.88 0.85 41.5 (15–141)* 0.55 0.46
NAS score: #4/$5 NA NA NA 53/47** 0.38 0.46
Fibrosis stage: #1/$2 60/40** 0.50 0.51 79/21** 0.33 0.41
Inflammation activity: #1/$2 62/38** 0.50 0.50 62/38** 0.33 0.43
Steatosis grade: #1/$2 91/9** 0.55 0.58 47/53** 0.11 0.13
Balloon Hepatocytes: #1/$2 NA NA NA 73/27** 0.46 0.43
Total Cholesterol (mg/dL) 177 (104–274)* 20.16 20.10 204.5 (141–288)* 0.36 0.11
LDL (mg/dL) 107 (46–195)* 20.09 20.03 113 (43–182)* 0.44 0.19
HDL (mg/dL) 46 (27–74)* 20.24 20.34 40 (25–74)* 0.25 0.24
Triglycerides (mg/dL) 104 (51–245)* 0.10 0.20 222.5 (75–879)* 20.14 20.18
Glucose (mg/dL) 104 (60–292)* 0.45 0.42 111 (77–302)* 20.19 20.21
Insulin resist. (HOMA score) 3.5 (0.6–12.2)* 0.39 0.34 6.6 (1.4–89.9)* 0.09 0.13
*median (range);
** (%).
doi:10.1371/journal.pone.0023937.t001
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and serum ALT and no correlation with serum HCV RNA [30].
This last report however didn’t observe a significant correlation
between serum miR-122 levels and fibrosis stage. In contrast to
miR-122, there is only limited information about miR-34a
expression in the liver and its regulation in chronic disease. We
found miR-34a levels to be largely undetectable in plasma from
healthy individuals but significantly increased to detectable levels
in patients with CHC or NAFLD. As for miR-122, miR-34a
plasma levels correlated with fibrosis severity. Further increase of
miR-34a should be evaluated in HCC as miR-34a was reported
linked to disease progression from normal liver through cirrhosis
to HCC [31]. While a positive correlation between intrahepatic
miR-21 expression and viral load, fibrosis or serum liver
transaminase levels was reported [18], we only observed a
marginal increase of miR-21 in late disease stages. In contrast,
miR-16 was highly elevated in early disease and slightly
decreased in advanced stages. Further decrease of miR-16 should
be evaluated in HCC [32].
Non-invasive assessment of liver fibrosis is a very important
goal in patients with chronic hepatitis C. miR-122 and miR-16
were more sensitive than ALT in detecting early stage disease in
the studied sets of patients. In addition, miR-122 and miR-34a
may have utility in assessing disease stage. Chronic viral infection
of the liver is associated with insulin resistance and also associated
with the development of hepatic steatosis. The severity of steatosis
has been well correlated with the degree of hepatic fibrosis and
the severity of insulin resistance [33,34]. Both miR-122 and miR-
34a levels correlated with fibrosis stage, inflammation activity,
steatosis grade and to a lesser extent to insulin resistance and
glucose levels in CHC patients. There was overall no correlation
with serum lipids at the exception of a small negative correlation
with high-density lipoprotein (HDL). This may result from the
fact that in CHC patients, disease severity is associated with lower
HDL levels [35]. Interest in applying non-invasive methods to
assess liver fibrosis in patients with NAFLD has increased in
recent years [36]. The overwhelming majority of persons with
elevated ALT activity in the absence of viral hepatitis or excessive
alcohol consumption are found to have NAFLD on liver biopsy in
the US and Europe [37]. miR-34a and miR-122 may have utility
in the identification of those NAFLD patients who have
developed significant liver fibrosis. Interestingly, in contrast to
CHC patients, mir-122 levels correlated with serum lipids in
NAFLD patients. Overall, the prospect of using miR-122 and
miR-34a as prognostic markers is of interest. Larger patient
cohorts with distinct hepatic disease-causes and differential
fibrosis states will have to be analyzed to further test the utility
of circulating miR-122 and miR-34a as biomarkers for detection
or monitoring of liver fibrosis.
Supporting Information
Table S1 Patients’ clinical information.
(DOC)
Acknowledgments
We thank Dr. Charles M. Rice (Rockefeller University, New York) for the
gift of the HCV J6/JFH strain and Huh7.5 cells, Dr. Muneesh Tewari and
Evan M. Kroh (Division of Human Biology, Fred Hutchinson Cancer
Research Center, Seattle) for helpful discussion and excellent advice, Paul
J. Farley (Public Health Sciences Division, Fred Hutchinson Cancer
Research Center, Seattle) and Erica V. Tartaglione (Division of
Figure 5. Receiver operating characteristic (ROC) analysis of expression of miRNAs in CHC and NAFLD patients. ROC curves with
corresponding area under the ROC curve (AUC) for (A): mir-122 and miR-16 from CHC-early versus controls; (B) mir-122 and miR-16 from NAFLD-SS
(NAS 1-4) versus controls; (C) miR-122 and miR-34a from CHC-early versus CHC-advanced; (D) miR-122 and miR-34a from NAFLD-SS(NAS 1-4) versus
NASH (NAS 5–7).
doi:10.1371/journal.pone.0023937.g005
Serum MicroRNAs in Chronic Liver Diseases
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23937Gastroenterology, Veterans Affairs Puget Sound Health Care System,
Seattle) for their contributions to the project coordination.
Author Contributions
Conceived and designed the experiments: LB SC GNI. Performed the
experiments: SC AR. Analyzed the data: SC LB. Wrote the paper: LB SC.
Provided patient samples: JAM GNI.
References
1. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008)
Circulating microRNAs as stable blood-based markers for cancer detection. Proc
Natl Acad Sci U S A 105: 10513–10518.
2. Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a
new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101:
2087–2092.
3. Brase JC, Wuttig D, Kuner R, Sultmann H (2010) Serum microRNAs as non-
invasive biomarkers for cancer. Mol Cancer 9: 306.
4. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, et al. (2006) miR-122
regulation of lipid metabolism revealed by in vivo antisense targeting. Cell
Metab 3: 87–98.
5. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, et al. (2005)
Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438: 685–689.
6. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, et al. (2010) Liver-enriched
transcription factors regulate microRNA-122 that targets CUTL1 during liver
development. Hepatology 52: 1431–1442.
7. Lewis AP, Jopling CL (2010) Regulation and biological function of the liver-
specific miR-122. Biochem Soc Trans 38: 1553–1557.
8. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, et al.
(2007) Cellular cofactors affecting hepatitis C virus infection and replication.
Proc Natl Acad Sci U S A 104: 12884–12889.
9. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, et al. (2008) microRNA-
122 stimulates translation of hepatitis C virus RNA. EMBO J 27: 3300–3310.
10. Jangra RK, Yi M, Lemon SM (2010) Regulation of hepatitis C virus translation
and infectious virus production by the microRNA miR-122. J Virol 84:
6615–6625.
11. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS (2009)
Loss of miR-122 expression in liver cancer correlates with suppression of the
hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526–3536.
12. Zeng C, Wang R, Li D, Lin XJ, Wei QK, et al. (2010) A novel GSK-3 beta-C/
EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in
human hepatocellular carcinoma. Hepatology 52: 1702–1712.
13. Filipowicz W, Grosshans H (2011) The liver-specific microRNA miR-122:
biology and therapeutic potential. Prog Drug Res 67: 221–238.
14. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, et al. (2008)
MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular
carcinoma. Hepatology 47: 1223–1232.
15. Aqeilan RI, Calin GA, Croce CM (2010) miR-15a and miR-16-1 in cancer:
discovery, function and future perspectives. Cell Death Differ 17: 215–220.
16. Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer:
rationale, strategies and challenges. Nat Rev Drug Discov 9: 775–789.
17. Mizuguchi Y, Mishima T, Yokomuro S, Arima Y, Kawahigashi Y, et al. (2011)
Sequencing and bioinformatics-based analyses of the microRNA transcriptome
in hepatitis B-related hepatocellular carcinoma. PLoS One 6: e15304.
18. Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, et al.
(2010) Correlation between microRNA expression levels and clinical parameters
associated with chronic hepatitis C viral infection in humans. Lab Invest 90:
1727–1736.
19. Hermeking H (2007) p53 enters the microRNA world. Cancer Cell 12: 414–418.
20. Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA, et al. (2010)
Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155,
and miR-200b is associated with strain-specific susceptibility to dietary
nonalcoholic steatohepatitis in mice. Lab Invest 90: 1437–1446.
21. Parent R, Qu X, Petit MA, Beretta L (2009) The heat shock cognate protein 70
is associated with hepatitis C virus particles and modulates virus infectivity.
Hepatology 49: 1798–1809.
22. Batts KP, Ludwig J (1995) Chronic hepatitis. An update on terminology and
reporting. Am J Surg Pathol 19: 1409–1417.
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver
disease. Hepatology 41: 1313–1321.
24. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, et al. (2011)
Argonaute2 complexes carry a population of circulating microRNAs indepen-
dent of vesicles in human plasma. Proc Natl Acad Sci U S A 108: 5003–5008.
25. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W (2009)
Decreased levels of microRNA miR-122 in individuals with hepatitis C
responding poorly to interferon therapy. Nat Med 15: 31–33.
26. Morita K, Taketomi A, Shirabe K, Umeda K, Kayashima H, et al. (2011)
Clinical significance and potential of hepatic microRNA-122 expression in
hepatitis C. Liver Int 31: 474–484.
27. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, et al. (2009) Circulating
microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad
Sci U S A 106: 4402–4407.
28. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, et al. (2010) Plasma microRNA-122
as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin
Chem 56: 1830–1838.
29. Xu J, Wu C, Che X, Wang L, Yu D, et al. (2011) Circulating microRNAs, miR-
21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic
hepatitis. Mol Carcinog 50: 136–142.
30. Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, et al.
(2011) Serum miR-122 as a biomarker of necroinflammation in patients with
chronic hepatitis C virus infection. Am J Gastroenterol.
31. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, et al. (2010) miR-221
overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107:
264–269.
32. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M (2011) Circulating microRNAs
as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol In press.
33. Negro F, Sanyal AJ (2009) Hepatitis C virus, steatosis and lipid abnormalities:
clinical and pathogenic data. Liver Int 29(Suppl 2): 26–37.
34. Sanyal AJ (2011) Role of insulin resistance and hepatic steatosis in the
progression of fibrosis and response to treatment in hepatitis C. Liver Int
31(Suppl 1): 23–28.
35. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, et al. (2011)
Serum lipids and their associations with viral levels and liver disease severity in a
treatment-naive chronic hepatitis C type 1-infected cohort. J Viral Hepat 18:
e144–152.
36. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley K, Chalasani N, et al. (2011)
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology.
37. Ioannou GN, Boyko EJ, Lee SP (2006) The prevalence and predictors of
elevated serum aminotransferase activity in the United States in 1999-2002.
Am J Gastroenterol 101: 76–82.
Serum MicroRNAs in Chronic Liver Diseases
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23937